Speak To An Expert
Get clear, personalised advice for your situation.
Jot down a few questions to make the most of your conversation.
Understanding clinical evidence for NHS access
When the NHS considers diabetes technologies such as continuous glucose monitors, insulin pumps, or hybrid closed-loop systems, it looks for clinical evidence that the device is safe, effective, and suitable for the person’s needs. This evidence helps clinicians decide whether a technology is likely to improve diabetes control and daily life.
Eligibility is not usually based on one single test result. Instead, NHS teams review the full clinical picture, including diabetes type, treatment history, glucose management, and whether the technology could realistically help.
Common evidence the NHS may look for
For many diabetes technologies, the NHS wants evidence of poor glucose control despite best efforts with current treatment. This may include a high HbA1c, frequent hypoglycaemia, or large swings in blood glucose levels.
Clinicians may also look for repeated episodes of severe hypoglycaemia, impaired awareness of hypos, or difficulty meeting treatment targets. For some people, frequent diabetic ketoacidosis, especially in type 1 diabetes, may also support access.
In addition, there may be evidence that the person is engaged with diabetes care and able to use the technology safely. This can include attending appointments, checking blood glucose regularly, and being willing to learn how the device works.
Evidence for specific technologies
Continuous glucose monitoring systems may be considered where there is a need for better real-time glucose data, such as frequent hypos, unhelpful blood glucose variability, or difficulty with finger-prick testing. The NHS may also consider whether the person would benefit from alerts for high or low glucose levels.
For insulin pumps, evidence often includes the need for intensive insulin management, difficulty achieving control on multiple daily injections, or problematic hypos. Some people may also be assessed on whether they would benefit from more flexible insulin delivery.
Hybrid closed-loop systems usually need evidence that the person is already using insulin therapy and would benefit from automated insulin adjustments. NHS teams may consider whether the technology could improve time in range, reduce hypos, and support safer day-to-day management.
What else can support a referral
Clinical evidence is stronger when it is supported by documented patterns over time rather than a single reading. Blood glucose logs, HbA1c history, hospital admissions, and clinic letters can all help show the need for a device.
It can also help if the person has tried standard treatments first and still has ongoing problems. This shows that the technology is being considered for a clear clinical reason, rather than as a first option.
Why local policies matter
NHS access can vary depending on local Integrated Care Board policies and specialist diabetes services. Some areas may use slightly different thresholds or additional criteria.
If access is being considered, a diabetes specialist team will usually review the evidence and decide whether the person meets local and national guidance. They may also discuss alternatives if the technology is not yet appropriate.
Frequently Asked Questions
NHS diabetes technologies eligibility clinical evidence refers to the criteria, research findings, and local or national policy used to decide whether a person should be offered diabetes technologies through the NHS, such as insulin pumps, continuous glucose monitors, flash glucose monitors, or hybrid closed-loop systems.
Eligibility depends on the specific technology and local NHS pathway, but it is usually based on clinical need, diabetes type, treatment challenges, glucose control, risk of hypoglycaemia, ability to use the device safely, and evidence that the technology is likely to improve outcomes.
The clinical evidence usually includes studies showing improvements in HbA1c, time in range, hypoglycaemia reduction, quality of life, reduced hospital admissions, and better self-management when the technology is used appropriately in the right patient group.
For insulin pumps, eligibility evidence often focuses on poor glycaemic control despite multiple daily injections, frequent or severe hypoglycaemia, dawn phenomenon, variable glucose levels, or specific clinical needs where pump therapy is expected to provide benefit.
Continuous glucose monitoring is generally supported when there is a clear clinical need for closer glucose tracking, such as frequent hypoglycaemia, impaired hypoglycaemia awareness, pregnancy, unstable glucose control, or when improved monitoring is likely to change treatment decisions.
Flash glucose monitoring eligibility usually depends on the need for frequent glucose checks, difficulties with finger-prick testing, risk of hypoglycaemia, or situations where trend data would improve day-to-day diabetes management and clinical outcomes.
Type 1 diabetes is often the main group studied for advanced diabetes technologies, and the evidence commonly shows benefit from insulin pumps, continuous glucose monitoring, and hybrid closed-loop systems in people who need tighter glucose control or have hypoglycaemia concerns.
For type 2 diabetes, eligibility is more selective and evidence is usually strongest for people using intensive insulin therapy who have significant glucose variability, recurrent hypoglycaemia, or a clear need for technology to support safe and effective insulin management.
Pregnancy can strengthen eligibility because tighter glucose targets are needed and the clinical evidence often supports use of continuous glucose monitoring or insulin pump therapy to improve glucose control and reduce risks to mother and baby.
For children and young people, evidence is considered for improved safety, better glucose control, reduced hypoglycaemia, easier family support, and better quality of life, with decisions also based on age, maturity, and ability to use the device safely.
Frequent hypoglycaemia or impaired awareness of hypoglycaemia strongly supports eligibility because the evidence shows glucose monitoring and pump-based technologies can reduce low-glucose episodes and improve safety.
HbA1c is often used as one marker of control, but it is not the only factor. NHS decisions also consider glucose variability, hypoglycaemia, time in range, and whether technology is likely to improve overall clinical outcomes.
Time in range is a key measure because it shows how often glucose levels stay within the target range. Better time in range is a common clinical goal used to support decisions about advanced diabetes technologies.
Local NHS policies can affect access because each area may interpret national guidance differently, use different referral pathways, or apply additional review criteria while still relying on the same overall evidence base.
Typical documentation includes recent glucose records, HbA1c results, history of hypoglycaemia, current treatment details, reasons for requesting the technology, and clinician notes showing that the technology is clinically appropriate.
In some cases a clinician may recommend technology outside standard criteria if there is a strong clinical reason, but this usually requires careful justification, review, and alignment with local NHS commissioning rules.
Eligibility and ongoing use are often reviewed regularly to check whether the technology is delivering the expected benefits, such as improved glucose control, fewer hypoglycaemic episodes, and better self-management.
Eligibility determines whether someone can access the technology, while clinical benefit looks at whether the technology is actually helping. NHS decisions should be based on both the evidence for benefit and the person's individual clinical circumstances.
Yes, quality of life is often part of the evidence because diabetes technologies may reduce burden, improve confidence, support flexibility, and lessen the daily strain of diabetes management.
Official guidance is usually found through NHS England, NICE, local integrated care system policies, and diabetes specialist services, which set out the evidence and criteria used for access decisions.
Ergsy Search Results
This website offers general information and is not a substitute for professional advice.
Always seek guidance from qualified professionals.
If you have any medical concerns or need urgent help, contact a healthcare professional or emergency services immediately.
Some of this content was generated with AI assistance. We've done our best to keep it accurate, helpful, and human-friendly.
- Ergsy carefully checks the information in the videos we provide here.
- Videos shown by Youtube after a video has completed, have NOT been reviewed by ERGSY.
- To view, click the arrow in centre of video.
- Most of the videos you find here will have subtitles and/or closed captions available.
- You may need to turn these on, and choose your preferred language.
- Go to the video you'd like to watch.
- If closed captions (CC) are available, settings will be visible on the bottom right of the video player.
- To turn on Captions, click settings.
- To turn off Captions, click settings again.